MARKET

VALN

VALN

Valneva SE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

33.42
-0.29
-0.86%
Pre Market: 33.10 -0.32 -0.96% 09:03 01/27 EST
OPEN
34.80
PREV CLOSE
33.71
HIGH
34.80
LOW
32.78
VOLUME
604
TURNOVER
--
52 WEEK HIGH
67.84
52 WEEK LOW
24.16
MARKET CAP
1.75B
P/E (TTM)
-10.5290
1D
5D
1M
3M
1Y
5Y
Valneva soars 12% amid start of COVID-19 booster vaccination in phase 3 trial
Valneva (VALN +12.8%) started booster vaccinations in adult participants in its phase 3 trial called Cov-Compare. The trial extension will evaluate a booster dose of VLA2001 in adults aged 18
Seekingalpha · 1d ago
Valneva Advances Booster Phase Of Its Cov-Compare COVID-19 Vaccine Trial
Valneva SE (NASDAQ: VALN) has 
Benzinga · 1d ago
BRIEF-Valneva Starts Booster Phase Of Cov-Compare Trial Of Its Inactivated COVID-19 Vaccine Candidate
reuters.com · 1d ago
NVTS, EVTL and ADGI among mid-day movers
Gainers: Aptorum (NASDAQ:APM) +34%. Vertical Aerospace Ltd. (NYSE:EVTL) +29%. DatChat (NASDAQ:DATS) +27%. Navitas Semiconductor (NYSE:NVTS) +27%. Luminar Technologies LAZR +23%. Adagio Therapeutics (NASDAQ:ADGI) +18%. Olink (publ) (NASDAQ:OLK) +17%. Icosav...
Seekingalpha · 6d ago
38 Stocks Moving In Thursday's Mid-Day Session
Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares rose 29.8% to $0.2550. Baudax Bio, last month, announced a $4.2 million registered direct offering.
Benzinga · 6d ago
Mid-Morning Market Update: Markets Open Higher; American Airlines Posts Narrower-Than-Expected Loss
Following the market opening Thursday, the Dow traded up 0.92% to 35,352.17 while the NASDAQ rose 1.61% to 14,570.49. The S&P also rose, gaining, 1.06% to 4,581.00.
Benzinga · 6d ago
Valneva (VALN) Up as COVID-19 Jab Neutralizes Omicron Variant
Three doses of Valneva's (VALN) inactivated COVID-19 vaccine candidate, VLA2001, neutralizes the Omicron variant of SARS-CoV-2, per data from preliminary lab studies. Shares rally.
Zacks · 6d ago
WW, GLBE and TASK among pre market losers
Star Equity (NASDAQ:STRR) -33% prices $14.25M stock offering. Valneva (NASDAQ:VALN) -19%. Global-E Online (NASDAQ:GLBE) -15%. G Medical Innovations (NASDAQ:GMVD) -12% issues correction to insider purchase. Aridis Pharmaceuticals (NASDAQ:ARDS) -8%. China HG...
Seekingalpha · 01/20 13:49
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VALN. Analyze the recent business situations of Valneva SE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

66.67%Strong Buy
33.33%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VALN stock price target is 65.42 with a high estimate of 69.38 and a low estimate of 63.44.
High69.38
Average65.42
Low63.44
Current 33.42
EPS
Actual
Estimate
-0.670.100.871.65
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Institutional Holdings
Institutions: 7
Institutional Holdings: 263.20K
% Owned: 0.50%
Shares Outstanding: 52.47M
TypeInstitutionsShares
Increased
0
0
New
4
15.57K
Decreased
2
201.23K
Sold Out
6
352.03K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About VALN
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Webull offers kinds of Valneva SE stock information, including NASDAQ:VALN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VALN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VALN stock methods without spending real money on the virtual paper trading platform.